1. Home
  2. WRBY vs IMNM Comparison

WRBY vs IMNM Comparison

Compare WRBY & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Warby Parker Inc.

WRBY

Warby Parker Inc.

HOLD

Current Price

$27.67

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$24.01

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WRBY
IMNM
Founded
2010
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.6B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
WRBY
IMNM
Price
$27.67
$24.01
Analyst Decision
Buy
Strong Buy
Analyst Count
11
10
Target Price
$27.10
$32.80
AVG Volume (30 Days)
3.8M
1.7M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
105.88
51.40
EPS
0.03
N/A
Revenue
$871,905,000.00
$6,941,000.00
Revenue This Year
$14.48
N/A
Revenue Next Year
$16.41
$1,127.34
P/E Ratio
$934.67
N/A
Revenue Growth
13.04
N/A
52 Week Low
$14.96
$7.96
52 Week High
$31.00
$27.65

Technical Indicators

Market Signals
Indicator
WRBY
IMNM
Relative Strength Index (RSI) 52.28 70.06
Support Level $21.16 $23.67
Resistance Level $27.59 $25.10
Average True Range (ATR) 1.68 1.19
MACD 0.03 0.66
Stochastic Oscillator 50.96 84.40

Price Performance

Historical Comparison
WRBY
IMNM

About WRBY Warby Parker Inc.

Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The Company provides holistic vision care by offering eyewear, contacts, and eye care directly to consumers through its integrated, omnichannel platform. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: